Understand the source comparison
Peptides Help with TBI Recovery: Comparison of Research Compounds
Cerebrolysin BDNF/NGF mimetic; TrkB receptor activation Human RCTs (moderate certainty) 30–50mL/day IV for 10–21 days Intravenous Strongest human evidence for TBI neuroprotection; most studied compound Dihexa HGF potentiation at c-Met receptor Preclinical only
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF mimetic; TrkB receptor activation
- Human RCTs (moderate certainty)
- 30–50mL/day IV for 10–21 days
- Intravenous
- Strongest human evidence for TBI neuroprotection; most studied compound
- Dihexa
- HGF potentiation at c-Met receptor
- Preclinical only
- 5mg/kg (animal models)
- Subcutaneous or oral
- Promising synaptogenic effects but no human TBI trials
- P21
- ROCK2 inhibition; axonal regeneration
- 1mg/kg (animal models)
- Subcutaneous
- Facilitates neuroplasticity but requires further human validation
- Thymalin
- Immunomodulation; systemic anti-inflammatory
- Small human trials (low certainty)
- 10mg IM daily for 10 days
- Intramuscular
- Reduces systemic inflammation; limited direct CNS evidence
- Semax
- ACTH analogue; BDNF upregulation
- Animal + observational human data
- 300–600mcg intranasal daily
- Intranasal
- Used clinically in Russia; minimal Western trial data